caa a22 4500 606156801 CHVBK 20210128100610.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10096-015-2437-3 doi (NATIONALLICENCE)springer-10.1007/s10096-015-2437-3 Systematic analysis of the relationship between antibiotic use and extended-spectrum beta-lactamase resistance in Enterobacteriaceae in a French hospital: a time series analysis [Elektronische Daten] [M.-A. Vibet, J. Roux, E. Montassier, S. Corvec, M.-E. Juvin, C. Ngohou, D. Lepelletier, E. Batard] The influence of hospital use of antibiotics other than cephalosporins and fluoroquinolones on extended-spectrum beta-lactamase (ESBL) resistance among Enterobacteriaceae is poorly known. Our objective was to explore the association between ESBL and hospital use of various classes of antibacterial agents. The relationship between monthly use of 19 classes of antibacterial agents and incidence of nosocomial ESBL-producing Enterobacteriaceae in a French hospital was studied between 2007 and 2013. Five antibiotic classes were significantly and independently associated with ESBL resistance. Uses of tetracyclines (link estimate ± SE, 0.0066 ± 0.0033), lincosamides (0.0093 ± 0.0029), and other antibacterial agents (0.0050 ± 0.0023) were associated with an increased incidence, while nitrofurantoin (−0.0188 ± 0.0062) and ticarcillin and piperacillin with or without enzyme inhibitor (−0.0078 ± 0.0031) were associated with a decreased incidence. In a multivariate model including 3rd- and 4th-generation cephalosporins, fluoroquinolones, amoxicillin, and amoxicillin-clavulanate, 3rd- and 4th-generation cephalosporins (0.0019 ± 0.0009) and fluoroquinolones (0.0020 ± 0.0008) were associated with an increased ESBL resistance, whereas amoxicillin and amoxicillin-clavulanate were not. Hospital use of tetracyclines and lincosamides may promote ESBL resistance in Enterobacteriaceae. Nitrofurantoin and ticarcillin and piperacillin with or without enzyme inhibitor should be considered as potential alternatives to broad-spectrum cephalosporins and fluoroquinolones to control the diffusion of ESBL resistance. Springer-Verlag Berlin Heidelberg, 2015 Vibet M.-A INSERM, U657 Pharmaco-épidémiologie et évaluation de l'impact des produits de santé sur les populations, Paris, France aut Roux J. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut Montassier E. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut Corvec S. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut Juvin M.-E Department of Microbiology and Infection Control, Centre Hospitalier Universitaire de Nantes, Nantes, France aut Ngohou C. Health Information Management Department, Centre Hospitalier Universitaire de Nantes, Nantes, France aut Lepelletier D. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut Batard E. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/10(2015-10-01), 1957-1963 0934-9723 34:10<1957 2015 34 10096 https://doi.org/10.1007/s10096-015-2437-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-015-2437-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vibet M.-A INSERM, U657 Pharmaco-épidémiologie et évaluation de l'impact des produits de santé sur les populations, Paris, France aut NATIONALLICENCE 700 1- Roux J. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut NATIONALLICENCE 700 1- Montassier E. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut NATIONALLICENCE 700 1- Corvec S. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut NATIONALLICENCE 700 1- Juvin M.-E Department of Microbiology and Infection Control, Centre Hospitalier Universitaire de Nantes, Nantes, France aut NATIONALLICENCE 700 1- Ngohou C. Health Information Management Department, Centre Hospitalier Universitaire de Nantes, Nantes, France aut NATIONALLICENCE 700 1- Lepelletier D. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut NATIONALLICENCE 700 1- Batard E. EA3826 Thérapeutiques cliniques et expérimentales des infections, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, 44000, Nantes, France aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/10(2015-10-01), 1957-1963 0934-9723 34:10<1957 2015 34 10096